Kulvinder Kochar Kaur

Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: July 28, 2025; Published: August 12, 2025

Abstract

Having reviewed the role of different significant phage’s in eradication of escalating antibiotics resistance and eradication of multi drug resistant Tuberculosis (MDR) epidemic in India resulting from etiopathogenetisc Mycobacterium Tuberculosis agent. The aim of this short communication’’ is emphasizing the part of corticioid fungi in treating future infections resulting from drug resistant bacteria. As per authors from Poland, the extracts from 58 species of corticioid fungi (phylum Basidiomycota), which basically belonged to the orders Hymenochaetales, Polyporales as well as Russulales, were evaluated for their hampering activity against five species of bacteria: Corynebacterium striatum, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, in addition to Staphylococcusaureus14 fungal species investigated, possessed moderate activity against just two bacteria, P. aeruginosa in addition to C. striatum; 17 species possessed activity against just C. striatum. The total hampering was found with quantities of extract 25 or 50 mg/mL. Thereby putative information whose presence has been accepted since 1940’s, however later not pursued has resurfaced with escalating antibiotics resistance, thereby dead trees having such corticioid fungi possessed significant bacteria in contrast to ones without corticioid fungi. Thereby this brings hope for replacing antibiotics with resistance developed due to misuse of antibiotics by we physicians, in generating therapies from derivatives of such corticioid fungi. Hopefully this would be translated in clinical scenario to combat antibiotics resistance or MDR.

Keywords: Antibiotics Resistance; Corticioid Fungi; Staphylococcus aureus; Klebsiella pneumoniae; Pseudomonas aeruginosa; MDR

References

1. Bernardy EE., et al. “Genotypic and phenotypic diversity of Staphylococcus aureus isolates from cystic fibrosis patient lung infections and their interactions with Pseudomonas aeruginosa”. mBio 11 (2020): e00735-20.
2. Chang RYK., et al. “Novel antimicrobial agents for combating antibiotic-resistant bacteria”. Advanced Drug Delivery Reviews 187 (2022): 114378.
3. Tamkin E., et al. “Airway Corynebacterium interfere with Streptococcus pneumoniae and Staphylococcus aureus infection and express secreted factors selectively targeting each pathogen”. Infection and Immunity 93 (2025): e0044524.
4. Limoli DH and Hoffman LR. “Help, hinder, hide and harm: What can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections?” Thorax 74 (2019): 684-692.
5. Jain N., et al. “Upper respiratory tract infections”. Indian Journal of Pediatrics 68 (2001): 1135-1138.
6. Cheung GYC., et al. “Pathogenicity and virulence of Staphylococcus aureus”. Virulence 12 (2021): 547-569.
7. Chang D., et al. “Clinical epidemiology, risk factors, and control strategies of Klebsiella pneumoniae infection”. Frontiers in Microbiology 12 (2021): 750662.
8. Baudet A., et al. “Pseudomonas aeruginosa infections in patients with severe COVID-19 in intensive care units: A retrospective study”. Antibiotics 13 (2024): 390.
9. Abavisani M., et al. “First global report about the prevalence of multi-drug resistant Haemophilus influenzae: A systematic review and meta-analysis”. BMC Infectious Disease 24 (2024): 90.
10. Marino A., et al. “Corynebacterium striatum bacteremia during SARS-CoV2 infection: Case report, literature review, and clinical considerations”. Infectious Disease Reports 14 (2022): 383-390.
11. Nwobodo DC., et al. “Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace”. Journal of Clinical Laboratory Analysis 14 (2022): e24655.
12. Lysakova V., et al. “Antibacterial and antifungal activity of metabolites from basidiomycetes: A review”. Antibiotics 13 (2024): 1026.
13. Abadi B., et al. “Antibiotics with antiviral and anti-inflammatory potential against COVID-19: A review”. Current Reviews in Clinical and Experimental Pharmacology 18 (2023): 51-63.
14. Larsson KH and Ryvarden L. “Corticioid fungi of Europe”. Vol. 1. Acanthobasidium—Gyrodontium; Fungiflora: Oslo, Norway (2021).
15. Hyde KD., et al. “The 2024 Outline of Fungi and fungus-like taxa”. Mycosphere 15 (2024): 5146-6239.
16. De Boer W and van der Wal A. “Interaction between saprotrophic basidiomycetes and bacteria”. The British Mycological Society Symposium Series 28 (2008): 143-153.
17. Sun H., et al. “The impacts of treatment with biocontrol fungus (Phlebiopsis gigantea) on bacterial diversity in Norway spruce stumps”. Biological Control 64 (2008): 238-246.
18. Folman LB., et al. “Impact of white-rot fungi on numbers and communitycomposition of bacteria colonizing beech wood from forest soil”. FEMS Microbiology Ecology 63 (2008): 181-191.
19. Ha LS., et al. “Dentipellin, a new antibiotic from culture broth of Dentipelli fragilis”. Journal of Antibiotics 74 (2021): 538-541.
20. Wilkins H and Harris GCM. “Investigation into the production of bacteriostatic substances by fungi. VI. Examination of thelarger Basidiomycetes”. Annals of Applied Biology 74 (1944): 538-541.
21. Mathieson J. “Antibiotics from Victorian Basidiomycetes”. Australian Journal of Experimental Biology and Medical Science 24 (1946): 57-62.
22. Wilkins WH. “Investigation into the production of bacteriostatic substances by fungi. Preliminary examination of more of thelarger Basidiomycetes and some of the larger Ascomycetes”. Annals of Applied Biology 33 (1946): 188-190.
23. Giannetti, B.M., et al. “Antibiotika aus Basidiomyceten, VI. Merulinsauren A, B und C,neue Antibiotika aus Merulius tremellosus Fr. und Phlebia radiata Fr. Z. Naturforsch. C”. 33 (1978): 807-816.
24. Zjawiony JK., et al. “Merulius incarnatus Schwein., a rare mushroom with highly selective antimicrobial activity”. International Journal of Medicinal Mushrooms 7 (2008): 365-366.
25. Cateni F., et al. “New biologically active epidioxysterols from Stereum hirsutum”. Bioorganic and Medicinal Chemistry Letters 17 (2007): 6330-6334.
26. Ferreira-Silva V., et al. “Antibacterial activity of ethyl acetate extract of Agaricomycetes collected in Northeast Brazil”. Current Research in Environmental and Applied Mycology 7 (2017): 267-274.
27. Tamrakar S., et al. “Antibacterial activity of Nepalese wild mushrooms against Staphylococcus aureus and Propionibacterium acnes”. Journal of Wood Science 63 (2017): 379-387.
28. Sevindik M., et al. “Bioactivity of EtOH and MeOH extracts of basidiomycetes mushroom (Stereumhirsutum) on atherosclerosis”. Archives of Razi Institute 76 (2021): 87-94.
29. , et al. “Antioxidant, antibacterial, and antifungal activity of Hymenochaete rubiginosa”. Indian Journal of Natural Products and Resources 13 (2022): 67-71.
30. Grey ABJ., et al. “Screening of fungi for antimycobacterial activity using a medium-throughput bioluminescence-based assay”. Frontiers in Microbiology 12 (2021): 739995.
31. Shibata S and Natori S. “Some observations on antibacterial activity of wood-rotting fungi”. The Pharmaceutical Society of Japan 72 (1952): 594-595.
32. Suay I., et al. “Screening of basidiomycetes for antimicrobial activities”. Antonie Van Leeuwenhoek 78 (2000): 129-139.
33. Rosa LH., et al. “Screening of Brazilian basidiomycetes for antimicrobial activity”. Memorias do Instituto Oswaldo Cruz 98 (2003): 967-974.
34. Zrimec MB., et al. “Screening for antibacterial activity in 72 species of wood-colonizing fungi by the Vibrio fisheri bioluminescence method”. Journal of Basic Microbiology 44 (2024): 407-412.
35. , et al. “Investigation of the Possible Antibacterial Effects of Corticioid Fungi Against Different Bacterial Species”. International Journal of Molecular Sciences 26 (2025): 3292.
36. Kulvinder Kochar Kaur., et al. “Eukaryotic Association besides their Impact on Human Health along with Disease- Therapeutic implications with Escalating Antibiotics Resistance-A Minireview”. World Journal of Advance Healthcare Research11 (2012): 1-12.
37. Kulvinder Kochar Kaur., et al. “Regulation of the Hurdles in Addition to the Obstacles Associated With the Eradication of Drug Resistant Tuberculosis Epidemic in India -Stress on the : National Tuberculosis Elimination Programme”. Acta Scientific Microbiology6 (2019): 1-8.

Citation

Citation: Kulvinder Kochar Kaur. “Innovative Use of Corticioid Fungi Derivatives for Therapy of Antibiotics Resistance to Robust Gram Positive and Gram Negative-Bacteria".Acta Scientific Microbiology 8.9 (2025): 19-24.

Copyright

Copyright: © 2025 Kulvinder Kochar Kaur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.